概括
Thy-1突变淋巴瘤表现出糖化缺陷,这是由于阻断了与脂质结合的寡糖体前体的合成. 突变细胞中的异常,内葡萄糖酶H抗性寡糖体表明糖蛋白前体形成中的缺陷.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 提-1是一种细胞表面糖蛋白,参与细胞与细胞相互作用.
- 糖基化是一种关键的翻译后修改,影响蛋白质功能.
- 类E补充组Ty-1-突变淋巴瘤呈现特定的糖化缺陷.
研究的目的:
- 为了确定E类Ty-1-突变淋巴瘤中的特定的糖化缺陷.
- 为了表征这些突变细胞中的脂结寡糖 (LLOs).
- 为了确定新合成的多上发现的异常寡糖的来源.
主要方法:
- 从Thy-1突变和野生型淋巴瘤细胞中分离和表征LLOs.
- 使用内葡萄糖酶H消化对LLOs的分析.
- 在从突变细胞中新合成的多上对寡糖的分析.
主要成果:
- 从突变细胞中分离出两个主要的LLO,两者都比野生类型LLO小.
- 突变的LLOs对内葡萄糖酶H的消化有抵抗力,与野生类型LLOs不同.
- 在突变细胞中新合成的聚酸上的寡糖糖也对内葡萄糖酶H有抗性.
结论:
- 在E类thy-1淋巴瘤中的糖化缺陷是LLO前体合成的阻碍.
- 在突变细胞中形成异常的,耐内糖酶H的LLOs.
- 这些异常的LLOs是突变细胞中糖蛋白质上耐固醇糖酶H抗性寡糖的可能来源.
相关概念视频
Glucose Transporters
15.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
15.2K
Diabetes Mellitus: Introduction
24
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and...
24
Type I Diabetes I: Introduction
45
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1...
45
Type I Diabetes III: Clinical Manifestations
26
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the...
26
Type II Diabetes I: Introduction
17
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
17
Hyperglycemia
25
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
25


